The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
April 26th 2024
A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.
Medical Crossfire®: Updates in Continuous Glucose Monitoring—Having the Important Conversations With Your Patients
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Metformin May Be Linked to Lower Risk of Death from Cardiovascular Disease
A meta-analysis of 40 previously published studies conducted by Elizabeth Selvin, PhD, MPH, of the Johns Hopkins Bloomberg School of Public Health, and colleagues has found that treatment with the diabetes drug metformin may be associated with a lower risk of death from cardiovascular disease.
Early invasive or selective invasive strategies for ACS patients
October 22nd 2008Treatment of stable patients with acute coronary syndrome (ACS) is controversial. Until recently, large randomized clinical trials had indicated that an "early" invasive strategy with routine cardiac catheterization reduced the likelihood of recurrent cardiovascular events when compared with a more "selective" approach, in which stable patients were referred to cardiac catheterization based on high-risk features on noninvasive stress imaging or because of a failure in initial medical therapy.
Incidence of death and MI associated with stopping clopidogrel after ACS
October 21st 2008Rates of death and myocardial infarction were assessed for a national sample of acute coronary syndrome patients after stopping clopidogrel. In the first 90 days after stopping treatment, patients experienced a nearly twofold increased risk of adverse events compared with subsequent follow-up intervals for patients treated medically without stents and for patients treated with coronary stents. This suggests a possible clopidogrel rebound effect, but additional studies are needed to support this hypothesis and to identify strategies to reduce early events after clopidogrel cessation.
Non–ST-segment elevation ACS: Should all patients undergo cardiac catheterization?
We performed a systematic review and meta-analysis of all clinical trials comparing routine invasive strategy with selective invasive strategy in patients with non–ST-segment elevation acute coronary syndrome. We did not find either strategy to offer an advantage over the other, even when we excluded trials that did not use coronary stents and glycoprotein IIb/IIIa inhibitors.
Intensive glycemic control has no effect on cardiovascular disease in type 2 diabetes
October 16th 2008The benefits of intensive glycemic control appear to be confined to microvascular disease, with 3 randomized controlled clinical trials failing to demonstrate a macrovascular benefit with intensive glycemic control in patients with type 2 diabetes.
Direct renin inhibition in the elderly
Hypertension may well be the most important public health issue facing society today.
Multivessel CAD in ACS patients: Four important implications
The article by Schwartzman and Brener (page 33) has 4 important implications for the treatment of acute coronary syndrome (ACS) patients who are found to have multivessel coronary artery disease (CAD) during diagnostic coronary angiography.
Rivaroxaban: A potential replacement for warfarin?
September 29th 2008Millions of people in the United States require chronic anticoagulation to prevent thromboembolism secondary to chronic atrial fibrillation (AF), pulmonary hypertension, mechanical valve replacements, and other prothrombotic conditions.